Akinaga S - Search Results

1

KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.

Soga S, Neckers LM, Schulte TW, Shiotsu Y, Akasaka K, Narumi H, Agatsuma T, Ikuina Y, Murakata C, Tamaoki T, Akinaga S. Soga S, et al. Among authors: akinaga s. Cancer Res. 1999 Jun 15;59(12):2931-8. Cancer Res. 1999. PMID: 10383157

2

Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol.

Ikuina Y, Amishiro N, Miyata M, Narumi H, Ogawa H, Akiyama T, Shiotsu Y, Akinaga S, Murakata C. Ikuina Y, et al. Among authors: akinaga s. J Med Chem. 2003 Jun 5;46(12):2534-41. doi: 10.1021/jm030110r. J Med Chem. 2003. PMID: 12773056

3

Development of radicicol analogues.

Soga S, Shiotsu Y, Akinaga S, Sharma SV. Soga S, et al. Among authors: akinaga s. Curr Cancer Drug Targets. 2003 Oct;3(5):359-69. doi: 10.2174/1568009033481859. Curr Cancer Drug Targets. 2003. PMID: 14529387 Review.

4

New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells.

Nakashima T, Ishii T, Tagaya H, Seike T, Nakagawa H, Kanda Y, Akinaga S, Soga S, Shiotsu Y. Nakashima T, et al. Among authors: akinaga s. Clin Cancer Res. 2010 May 15;16(10):2792-802. doi: 10.1158/1078-0432.CCR-09-3112. Epub 2010 Apr 20. Clin Cancer Res. 2010. PMID: 20406843

5

Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.

Soga S, Akinaga S, Shiotsu Y. Soga S, et al. Among authors: akinaga s. Curr Pharm Des. 2013;19(3):366-76. doi: 10.2174/138161213804143617. Curr Pharm Des. 2013. PMID: 22920907 Review.

6

Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities.

Agatsuma T, Ogawa H, Akasaka K, Asai A, Yamashita Y, Mizukami T, Akinaga S, Saitoh Y. Agatsuma T, et al. Among authors: akinaga s. Bioorg Med Chem. 2002 Nov;10(11):3445-54. doi: 10.1016/s0968-0896(02)00260-2. Bioorg Med Chem. 2002. PMID: 12213458

7

Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models.

Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Akinaga S, et al. Cancer Res. 1991 Sep 15;51(18):4888-92. Cancer Res. 1991. PMID: 1893379

8

Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway.

Soga S, Kozawa T, Narumi H, Akinaga S, Irie K, Matsumoto K, Sharma SV, Nakano H, Mizukami T, Hara M. Soga S, et al. Among authors: akinaga s. J Biol Chem. 1998 Jan 9;273(2):822-8. doi: 10.1074/jbc.273.2.822. J Biol Chem. 1998. PMID: 9422737 Free article.

9

Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.

Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, Soga S, Murakata C, Tamaoki T, Akinaga S. Shiotsu Y, et al. Among authors: akinaga s. Blood. 2000 Sep 15;96(6):2284-91. Blood. 2000. PMID: 10979978 Free article.

10

Stereospecific antitumor activity of radicicol oxime derivatives.

Soga S, Sharma SV, Shiotsu Y, Shimizu M, Tahara H, Yamaguchi K, Ikuina Y, Murakata C, Tamaoki T, Kurebayashi J, Schulte TW, Neckers LM, Akinaga S. Soga S, et al. Among authors: akinaga s. Cancer Chemother Pharmacol. 2001 Dec;48(6):435-45. doi: 10.1007/s002800100373. Cancer Chemother Pharmacol. 2001. PMID: 11800023

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters